In recent years, the in vitro diagnostic (IVD) industry in China has encountered unprecedented development opportunities driven by multiple factors such as the continuous growth of global medical demand, technological progress, and population aging. By 2025, the size of China's IVD market is expected to exceed 135 billion yuan, becoming an indispensable and important component of the modern healthcare system.
Industry status: Steady growth, diverse highlights in segmented fields
The IVD industry in China has shown a steady growth trend in recent years. According to market research institutions, the size of China's IVD market has reached 125 billion yuan in 2024, a year-on-year increase of 8.5%. It is expected that by the end of 2025, the market size will exceed 135 billion yuan, with a growth rate maintained at around 8%. In the segmented field, immunodiagnosis still holds the largest market share, thanks to the continuous development of technologies such as chemiluminescence and electrochemiluminescence. Its applications in infectious diseases, tumor markers, thyroid function and other detection projects are becoming increasingly widespread. Molecular diagnostics, as the fastest growing sub field, has an average annual growth rate of about 20%. The continuous innovation of technologies such as PCR, NGS, dPCR, etc. has promoted their widespread application in infectious disease diagnosis, tumor gene testing, and other fields. The POCT market, with its fast and convenient characteristics, has a strong demand in primary healthcare, emergency treatment and other scenarios, and is expected to maintain a high growth rate in the coming years.
Technological innovation: the core driving force for industry development
Technological innovation is a key factor driving the development of the IVD industry. In the field of immunodiagnosis, the integration of chemiluminescence technology with microfluidics and AI has become an important trend, greatly improving the sensitivity and automation level of detection. In the field of molecular diagnostics, the continuous optimization and upgrading of PCR technology, especially the application of digital PCR (dPCR), has further improved the accuracy of detection, providing strong support for tumor liquid biopsy, rare disease gene detection, and so on. POCT technology is developing towards miniaturization, intelligence, and multi index joint inspection. By combining IoT and AI technology, it achieves real-time transmission and intelligent analysis of detection data, meeting the needs of primary healthcare, home self inspection, and other scenarios.
Competitive landscape: Market reshuffle under diversified situation
The competitive landscape of China's IVD industry is showing a diversified trend, with foreign-funded enterprises and local enterprises competing on the same stage. Foreign funded enterprises dominate the high-end market with advanced technology and brand advantages, but with the continuous breakthroughs in local enterprise technology and the improvement of product quality, their market share is gradually being squeezed. Local enterprises, relying on cost advantages, in-depth understanding of the local market, and policy support, occupy a large share in the mid to low end market and continuously penetrate into the high-end market. The implementation of centralized procurement policy and the promotion of medical insurance payment reform have accelerated market reshuffle, putting greater pressure on small and medium-sized enterprises to survive, and further concentrating market share towards top enterprises.
Future trend: Emerging markets and international development become new growth points
Looking ahead, the IVD industry in China will continue to maintain a stable growth trend. With the continuous growth of medical demand, the promotion of technological innovation, and the optimization of policy environment, the industry scale will continue to expand. Emerging markets such as pet medical testing and consumer health testing will become new growth points, bringing new development opportunities to the IVD industry.
As an upstream IVD reagent raw material manufacturer, Hubei Xindesheng Company can supply a variety of raw materials suitable for molecular diagnostics and other fields, including biological buffering agents, luminescent reagents, enzyme reaction substrates, etc. Hubei Xindesheng Material Technology Co., Ltd. has always maintained the research and development production philosophy of "exploring and innovating, pursuing excellence" in the face of current challenges and opportunities. At the same time, it actively expands overseas markets, participates in international competition, and enhances its international market share.
Your message must be between 20-3,000 characters!
